January 6, 2017January 6, 2017

Past Decade Saw Many New Therapies for NSCLC, but Modest Survival Benefit for Patients

Lung Cancer, News

The past decade saw the development of several new therapies for non-small cell lung cancer (NSCLC), but little survival benefit for patients with advanced-stage disease, according to a new study ... Read more

June 27, 2016June 27, 2016

Cost of Cystic Fibrosis Therapy Orkambi too High for Low Benefit, Say U.K.’s NICE

Cystic Fibrosis, News

The U.K.’s National Institute for Health and Care Excellence (NICE) announced that is does not recommend funding a cystic fibrosis (CF) treatment Orkambi through Vertex Pharmaceuticals at this time. In March, ... Read more